5.2.2. prostate-specific antigen. prostate-specific antigen (a glycoprotein enzyme secreted prostate epithelial cells) primary test suspicion pca. use serum marker revolutionised pca diagnosis . prostate-specific antigen organ- cancer specific; therefore, may elevated benign prostatic hyperplasia (bph), prostatitis non-malignant conditions. agreed standards defining psa thresholds . continuous parameter, higher levels indicating greater likelihood pca. men may harbour pca despite low serum psa . table 5.2 demonstrates occurrence pca isup ≥ grade 2 pca systematic biopsies low psa levels, precluding optimal psa threshold detecting non-palpable cspca. table 5.2: risk pca identified systemic pca biopsy relation low prostate-specific antigen values psa level (ng/ml)risk pca (%)risk isup grade > 2 pca (%)0.0–0.56.60.80.6–1.010.11.01.1–2.017.02.02.1–3.023.94.63.1–4.026.96.7 screening situation, commonly applied threshold psa ≥ 3.0 ng/ml, resulting 16.5% invited men returning positive test . risk finding pca specific psa threshold clinical cohort may different screening situation, due differences prevalence, protocol referral, diagnostic algorithm. psa keeps diagnostic value cancer detection symptomatic patients . review meta-analysis diagnostic accuracy psa (≥ 4.0 ng/ml) detection pca transrectal ultrasound (trus) clinical patients found estimated combined sensitivity 0.93 specificity 0.20 psa production androgen dependent 5a-reductase inhibitors (e.g. finasteride, dutasteride) used benign prostatic enlargement prostate finasteride dutasteride reduce psa levels 50% . cases, psa level corrected decision investigation made. case moderately elevated psa (up 10 ng/ml), repeated test weeks considered confirm increase going continue diagnostic analysis. repeat psa performed laboratory using assay standardised conditions (i.e. ejaculation, manipulations, urinary tract infections [utis]) . type psa assay used may impact psa values rates psa certain fixed thresholds . repeat psa test prostate biopsies men initial psa 3–10 ng/ml reduced indication biopsies 16.8% men missing 5.4% isup grade > 1 stockholm3 trial . similarly, prostate testing cancer treatment (protect) trial men 20% lower repeat-psa analysis within seven weeks lower risk pca (or: 0.43, 95% ci: 0.35–0.52) well lower risk isup grade ≥ 2 (or: 0.29, 95% ci: 0.19–0.44) . study psa interval four weeks showed similar findings reduced risk pca isup grade > 1 . observations indicate early repeat-psa prior decision prostate biopsies prognostic information.